EFFECTS OF MODULATING KDM5B EXPRESSION IN PROSTATE CANCER CELLS

Aukse Versekenaite1, Ruta Maleckaite1, Kristina Daniunaite1

1 Vilnius University, Life Sciences Center, Institute of Biosciences, Vilnius, Lithuania

Prostate cancer (PCa) remains one of the leading causes of death among men, with over 370,000 annual deaths worldwide [1]. It has become evident that epigenetics plays a significant role in the onset and progression of PCa, particularly histone methylation and its associated genes. One of these genes is KDM5B, a lysine-specific demethylase, which has been identified in recent years as an oncogene associated with many cancers [2]. In PCa, KDM5B is often overexpressed, which correlates with lower patient survival rates [3]. Therefore, lowering KDM5B expression in cancer cells could be a potential target for PCa treatment.

This study aimed to modulate KDM5B gene expression in PCa cells by transfection with small interfering RNA (siRNA) and to assess the induced potential changes in cell behavior. PC-3 and LNCaP cell lines were used for this study. The relative expression of KDM5B was measured using quantitative PCR, and commercial assays were used to assess cell viability, proliferation, invasiveness, and migration.

Our preliminary results demonstrated successful downregulation of KDM5B expression in both cell lines following siRNA transfection, with the statistically significant decrease observed in LNCaP cells (P < 0.01). Functional analyses revealed that KDM5B silencing reduced PC-3 cell viability and proliferation (P = 0.0125 and P = 0.0190, respectively), while no significant changes in apoptotic or necrotic cell populations were detected. Furthermore, decreased migratory capacity was observed in both PC-3 and LNCaP cells, suggesting a potential role of KDM5B in regulating prostate cancer cell motility.

In conclusion, our preliminary results indicate that siRNA-mediated downregulation of KDM5B expression in PCa cells reduces cell viability, proliferation, and migration, suggesting a potential role in PCa progression and its relevance for drug development.


[1] C. Boixareu, T. Taha, V. B. Venkadakrishnan, J. De Bono, and H. Beltran, “Targeting the tumour cell surface in advanced prostate cancer,” Nature Reviews Urology, vol. 22, no. 9, pp. 569–589, Apr. 2025, doi: 10.1038/s41585-025-01014-w.

[2] Y.-D. Fu et al., “Targeting histone demethylase KDM5B for cancer treatment,” European Journal of Medicinal Chemistry, vol. 208, p. 112760, Aug. 2020, doi: 10.1016/j.ejmech.2020.112760.

[3] B. Liu et al., “Evidence for context-dependent functions of KDM5B in prostate development and prostate cancer,” Oncotarget, vol. 11, no. 46, pp. 4243–4252, Nov. 2020, doi: 10.18632/oncotarget.27818.